Will FMC's FY2026 adjusted EBITDA fall below the $670M guidance floor?

FMC's guidance track record is the dominant signal. FY2025 EBITDA guidance was cut from >$1B to $830-870M — a reduction of ~15-20%. If a similar pattern applies to 2026, the $670-730M range could be reduced to $570-620M. However, the 2026 guidance was set with full knowledge of the prior misses and CEO Brondeau's explicit acknowledgment of past overoptimism. The 2026 guidance already embeds the trough assumption. The resolution includes 'or if FMC cuts guidance below $670M at any point during 2026,' which broadens YES conditions significantly — even a mid-year cut that is later recovered would trigger YES. This broader condition pushes probability up. ~45% reflects the track record of overoptimism applied to a range that is already depressed but still potentially optimistic.

The $670M floor is already a significant step-down from FY2025's ~$850M — roughly 21% lower. Management may have finally set achievable targets given the pain of FY2025 misses. The 2026 headwinds are largely known and quantified: Rynaxypyr generic competition, manufacturing cost restructuring, tariffs, Q1 seasonal weakness. The unknown is the pace of generic erosion in the first full year post-patent. If Rynaxypyr branded sales decline faster than management's flat-earnings target, and core portfolio erosion continues, the $670M floor could be at risk. However, the earnings-weighted Q3/Q4 provide room for H2 recovery that could offset any H1 softness. ~40% probability.

The critical input is whether the 2026 guidance incorporates the lessons of FY2025 or repeats the overoptimism pattern. CEO Brondeau returning to lead the turnaround suggests heightened accountability, but his 'mid-teens growth in 2027-2028' targets suggest continued optimism about the recovery speed. The resolution criteria's inclusion of any guidance cut at any point during 2026 is significant — even if FMC ultimately achieves $670M+ for the full year, a mid-year cut below $670M would resolve YES. Companies frequently cut guidance at Q1 or Q2 results if the year starts poorly, then raise it later. Given Q1 is guided at only $45-50M, any softness could trigger a full-year guidance cut.

The base rate for FMC guidance accuracy is poor — FY2025 was a significant miss. The question is whether management has calibrated expectations for 2026. The $670-730M range already represents a ~21% decline from FY2025. However, this is the first full year of Rynaxypyr generic competition, and the magnitude of erosion is genuinely uncertain. Core portfolio restructuring benefits don't fully materialize until 2027. New AI revenue missed the 2025 target. Multiple risk factors could individually push EBITDA below $670M. The broad resolution criteria (any guidance cut) add probability. ~42%.

The $670M floor represents management's worst-case scenario within their range. Companies typically set guidance ranges where the bottom end is achievable even in a negative scenario — the idea is to avoid ever going below the floor. FMC set this range after the credibility damage of FY2025 cuts, creating strong incentive to set a genuinely conservative floor. Additionally, the insider buying at $13.83 post-guidance announcement suggests insiders believe the plan is achievable. However, Rynaxypyr's first full year of generic competition adds genuine uncertainty. ~38% reflects cautious optimism that the floor was set conservatively.

Two opposing forces: (1) management has pattern of overoptimism (FY2025), suggesting the $670M floor may still be too high — probability UP; (2) management set this guidance after absorbing FY2025 lessons and has strong credibility incentive to be conservative — probability DOWN. The resolution criteria tilt toward YES because any guidance cut at any point triggers it. Companies in FMC's position frequently provide wider-than-normal guidance ranges and may adjust within the year. Net assessment: ~40% probability, reflecting genuine uncertainty about execution in the first full year of generic competition.

FY2025 guidance was cut from >$1B to $830-870M. If pattern repeats with 15% haircut, $670M becomes ~$570M. But 2026 guidance set with awareness of prior misses. Resolution includes any guidance cut — broadens YES conditions. ~40% balances track record vs improved conservatism.

Multiple risk factors: Rynaxypyr generic competition (first full year), core portfolio erosion, tariffs, manufacturing restructuring costs. Any of these could push EBITDA below $670M. Management's track record suggests overoptimism is structural, not situational. The broad resolution criteria make YES more likely. ~45%.

The guidance floor of $670M is already depressed. But management has consistently overestimated performance. First full year of generic competition adds uncertainty. Insider buying provides some counterweight. ~42% probability reflecting the balance of negative track record and improved conservatism.